首页> 外文期刊>Diabetes >FGF21 Is a Hormonal Mediator of the Human 'Thrifty' Metabolic Phenotype
【24h】

FGF21 Is a Hormonal Mediator of the Human 'Thrifty' Metabolic Phenotype

机译:FGF21是人类“节俭”代谢表型的激素介体

获取原文
获取原文并翻译 | 示例
       

摘要

Fibroblast growth factor 21 (FGF21) regulates energy expenditure (EE) and influences weight change during low-protein overfeeding in rodent models. The change in EE after a low-protein overfeeding diet is a predictor of weight change in humans and a feature of the "thrifty" metabolic phenotype. However, there are no studies showing an association between circulating FGF21 and diet-related EE in humans. We assessed the changes in plasma FGF21 concentrations after 24 h of seven dietary interventions with different macronutrient content while in a whole-room indirect calorimeter in 64 healthy subjects with normal glucose regulation. Plasma FGF21 concentration consistently increased by threefold only after the two low-protein (3%) overfeeding diets, one high in carbohydrate (75%) and the other high in fat (46%), with larger increases in FGF21 being associated with greater increases in 24-h EE. Subjects with smaller increases in FGF21 after the low-protein high-fat diet gained more weight after 6 months in free-living conditions. Therefore, the individual predisposition to weight gain over time can be assessed by 24-h overfeeding a low-protein diet and measurements of plasma FGF21 concentrations. Individuals with a blunted FGF21 response to a low-protein diet have a thrifty metabolism and are at risk for future weight gain.
机译:在啮齿动物模型中,成纤维细胞生长因子21(FGF21)调节能量消耗(EE)并影响低蛋白过量喂养期间的体重变化。低蛋白饮食过量后,EE的变化是人类体重变化的预测指标,也是“节俭”代谢表型的特征。但是,尚无研究表明人体内循环FGF21与饮食相关的EE之间存在关联。我们评估了64名健康受试者中葡萄糖含量正常的7种饮食干预措施在24小时后血浆中FGF21浓度的变化。仅在两种低蛋白(3%)过量喂养,一种高碳水化合物(75%)和另一种高脂肪(46%)的饮食之后,血浆FGF21浓度始终增加了三倍,其中FGF21的增加越大与增加越大有关在24小时EE中。低蛋白高脂饮食后FGF21增长幅度较小的受试者在自由生活条件下6个月后体重增加。因此,可以通过过量饲喂低蛋白饮食24小时和测量血浆FGF21浓度来评估个体随时间增长的倾向。对低蛋白饮食的FGF21反应迟钝的个体会节俭代谢,并有可能将来体重增加。

著录项

  • 来源
    《Diabetes》 |2019年第2期|318-323|共6页
  • 作者单位

    Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ,Endocrinology Division, Medicine Department, Phoenix VA Health Care System, Phoenix, AZ;

    Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ;

    Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ;

    Clinical Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD;

    Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ;

    Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 04:08:38

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号